clinical trials
-
Tislelizumab regimen reached 45.3% pathological complete response in rectal cancer
In this 118-patient randomised phase II trial, adding tislelizumab to short-course radiotherapy and CAPOX chemotherapy was associated with a higher pathological complete response rate than the same treatment…
-
Cetuximab-irinotecan produced 18.8 versus 10.4 months median survival
In a 68-patient exploratory randomised trial, rechallenge with cetuximab plus irinotecan produced longer median progression-free and overall survival than regorafenib. The result is promising but comes from one…
-
Radiation boost improved nine-year disease-free survival by 23 percentage points
In a 106-person randomised phase II trial in locally advanced rectal cancer, a higher-dose radiation boost during preoperative chemoradiotherapy was associated with better nine-year disease-free and overall survival.…
-
AI assistance detected adenomas in 33.8% versus 30.9% in Lynch surveillance
In this randomised trial across nine specialist centres, adding the CAD EYE artificial intelligence system to high-definition colonoscopy did not significantly increase adenoma detection in people with Lynch…
-
Intensified preoperative treatment improved 3-year disease-free survival by 8.8 points
In a 458-patient randomised trial of high-risk locally advanced rectal cancer, a chemotherapy-intensified total neoadjuvant therapy regimen produced higher 3-year disease-free survival than conventional chemoradiotherapy. It also caused…